---
schema_version: "secwatch.filing_event.v1"
accession: "0001725160-24-000007"
form_type: "8-K"
ticker: "ZNTL"
cik: "0001725160"
company_name: "Zentalis Pharmaceuticals, Inc."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:24:26.697689+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Zentalis licenses ROR1 ADC ZPC-21 to Immunome for $35M upfront, up to $275M milestones

## Summary
- Exclusive worldwide license of preclinical ROR1 ADC ZPC-21 and proprietary ADC platform to Immunome.
- Zentalis receives $35M upfront in cash and Immunome common stock; eligible for up to $275M milestones plus mid-to-high single-digit royalties.
- Immunome plans to submit IND for ZPC-21 in 1Q 2025.
- Zentalis to focus resources on advancing azenosertib (WEE1 inhibitor) in multiple clinical studies.

## SEC filing metadata
- accession: 0001725160-24-000007
- form_type: 8-K
- ticker: ZNTL
- cik: 0001725160
- company_name: Zentalis Pharmaceuticals, Inc.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1725160/000172516024000007/0001725160-24-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1725160/000172516024000007/zntl-20240105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001725160-24-000007
- JSON: https://secwatch.observer/filing/0001725160-24-000007.json
- Plain text: https://secwatch.observer/filing/0001725160-24-000007.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.